James Brown, proceeding pro se, filed a diversity products liability lawsuit against E.T. Browne Drug Company in the Northern District of Georgia. Brown alleged that the use of a hydroquinone cream sold by the defendant caused him permanent skin damage known as exogenous ochronosis. The district court dismissed the complaint under Federal Rule of Civil Procedure 12(b)(6), ruling that the claims were time-barred. Brown appealed, arguing that the district court misapplied Georgia's accrual law and that the statute of limitations should have been tolled under the discovery rule until the date of his 'loss' in 2022.
The Eleventh Circuit reviewed the dismissal de novo, applying Georgia substantive law as required in diversity actions. The court explained that under O.C.G.A. § 9-3-33, personal injury actions must be brought within two years of accrual, while O.C.G.A. § 51-1-11(b)(2) imposes a ten-year statute of repose for strict liability claims. The court noted that while Georgia's discovery rule can delay accrual for injuries that develop over an extended period, it does not apply when a plaintiff discovers the injury and its cause within the statutory window. The court found that Brown's own medical records and his concession in the district court established that he was diagnosed with the injury in November 2021 and suspected the cause was the hydroquinone cream at that time. Consequently, the two-year limitations period expired in November 2023, but Brown did not file suit until November 2024. Furthermore, the court rejected the statute of repose argument, noting that Brown began using the product at age 15 and was 33 when the injury was diagnosed, meaning more than ten years had passed since the first sale. The court also clarified that the district court properly considered the defendant's medical records in ruling on the motion to dismiss, as they were central to the claim and undisputed.
The judgment dismissing Brown's lawsuit remains in effect, permanently barring him from pursuing personal injury claims against E.T. Browne Drug Company based on this incident. The decision reinforces that pro se litigants cannot rely on the discovery rule to extend filing deadlines when medical records or their own admissions show they were aware of the injury and its cause well before the limitations period expired. It also confirms that the ten-year statute of repose acts as an absolute bar for product liability claims where the product was sold more than a decade prior to the injury diagnosis.
Podcast (federal-narrative-summaries): Play in new window | Download